Oct 20 (Reuters) - NanoViricides Inc NNVC.A:
NANOVIRICIDES: CLINICAL LEAD DRUG NV-387 HAS SHOWN STRONG ACTIVITY AGAINST MEASLES VIRUS IN A HUMANIZED ANIMAL MODEL
NANOVIRICIDES: NV-387 CAN NOW BE MADE AVAILABLE FOR EMERGENCY USE APPLICATION IN MEASLES PATIENTS TO RESPOND TO SPREADING MEASLES OUTBREAKS
NANOVIRICIDES: NV-387 HAS ALREADY COMPLETED PHASE I CLINICAL TRIAL IN HEALTHY SUBJECTS WITH NO REPORTED ADVERSE EVENTS
Further company coverage: NNVC.A
((((Reuters.Briefs@thomsonreuters.com));))